WILSON JOHN S 4

4 · BOND LABORATORIES, INC. · Filed Nov 13, 2012

Form 4

Period: 2012-11-06

DirectorCHIEF EXECUTIVE OFFICER

Transactions

Purchase
Common Stock
2012-11-06+1,399,352→ 2,649,006 total
Purchase
Series B Convertible Preferred Stock
2012-11-06+8.77→ 8.77 total
Exercise: $0.00→ Common Stock (526,200 underlying)

Holdings

Stock Option
Exercise: $0.09From: 2012-05-09Exp: 2017-04-13→ Common Stock
500,000
Stock Option
Exercise: $0.10From: 2011-06-08Exp: 2021-06-08→ Common Stock (500,000 underlying)
500,000
Warrant
Exercise: $0.15From: 2008-12-31Exp: 2013-12-31→ Common Stock (1,000,000 underlying)
1,000,000
Series C Convertible Preferred Stock
Exercise: $0.25→ Common Stock (668,000 underlying)
16.7
Warrant
Exercise: $0.30Exp: 2015-11-15→ Common Stock (332,500 underlying)
332,500

Footnotes (5)

[F1]Mr. Wilson acquired the shares of common stock, as well as the shares of Series B Convertible Preferred Stock reported in Table II ("Series B Preferred"), for aggregate consideration of $50,000, in a private transaction.
[F2]The Series B Preferred convert, without additional consideration, into shares of the Issuer's common stock on a 1-for-60,000 basis.
[F3]The Series B Preferred, Series C Convertible Preferred Stock ("Series C Preferred") and Warrants are immediately convertible, or exercisable, as the case may be.
[F4]The Series B Preferred and Series C Preferred are perpetual.
[F5]The Series C Preferred convert on a 1-for-40,000 basis.

Documents

1 file